{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:49:57Z","timestamp":1794962997477,"version":"4.9.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:p>Cefazolin, a first-generation cephalosporin, is critical for treating infections and preventing orthopedic perioperative infections, but its real-world adverse event (AE) spectrum remains unclear. This study identifies safety signals using data from the U.S. Food and Drug Administration AE Reporting System (FAERS). A retrospective pharmacovigilance study analyzed FAERS data (Q1 2004\u2013Q1 2024). Disproportionality analysis was performed using a case\/non-case design, calculating the reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma poisson shrinker (MGPS) to assess the frequency and disproportionality of AEs. The \u201ccases\u201d were reports listing cefazolin as the primary suspect drug, while the \u201cnon-cases\u201d comprised all other reports in FAERS. 1896 cefazolin-related AE reports were included (50.45% male; 45\u201365 age group dominant). 70.08% occurred within 1 week, mainly \u201cserious events\u201d (39.13%) and \u201chospitalization\u201d (34.04%). Key SOCs: immune system disorders (488 cases, ROR\u2005=\u20058.72), skin disorders (815 cases, ROR\u2005=\u20052.95), hepatobiliary disorders (137 cases, ROR\u2005=\u20052.7). Significant signals: anaphylactic shock (ROR\u2005=\u200548.37) and acute generalized exanthematous pustulosis (ROR\u2005=\u200551.8). Critical safety risks of cefazolin are identified, highlighting the need for enhanced AE monitoring. Further research is required to clarify mechanisms and improve safety evaluation.<\/jats:p>","DOI":"10.1097\/md.0000000000046293","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:02:08Z","timestamp":1765814528000},"page":"e46293","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["A real-world pharmacovigilance study of FDA adverse event reporting system events for cefazolin"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3538-0872","authenticated-orcid":false,"given":"Jiaqi","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Orthopedics, The Affiliated Hospital of Beihua University, Jilin, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Affiliated Hospital of Beihua University, Jilin, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Affiliated Hospital of Beihua University, Jilin, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HuaiXi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Affiliated Huai\u2019an Hospital of Xuzhou Medical University, Huaian, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251215","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1097\/JS9.0000000000001882","article-title":"Antibiotic prophylaxis for surgical wound infections in clean and clean-contaminated surgery: an updated systematic review and meta-analysis.","volume":"110","author":"Tang","year":"2024","journal-title":"Int J Surg"},{"key":"R2-20251215","doi-asserted-by":"crossref","first-page":"10509","DOI":"10.1038\/s41467-024-54432-6","article-title":"Cefazolin shifts the kidney microbiota to promote a lithogenic environment.","volume":"15","author":"Agudelo","year":"2024","journal-title":"Nat Commun"},{"key":"R3-20251215","doi-asserted-by":"crossref","first-page":"e2429702","DOI":"10.1001\/jamanetworkopen.2024.29702","article-title":"Tourniquet use and local tissue concentrations of cefazolin during total knee arthroplasty: a randomized clinical trial.","volume":"7","author":"Montreuil","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ajog.2024.03.019","article-title":"Cefazolin as the mainstay for antibiotic prophylaxis in patients with a penicillin allergy in obstetrics and gynecology.","volume":"231","author":"Dutra","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"R5-20251215","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11882-024-01171-9","article-title":"Cephalosporin allergy: updates on diagnostic testing.","volume":"24","author":"Chow","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"R6-20251215","first-page":"167","article-title":"Hypoprothrombinemia and severe perioperative haemorrhagic complications in cardiac surgery patients treated with high-dose cefazolin for infective endocarditis.","volume":"37","author":"Angles","year":"2018","journal-title":"Anaesth Crit Care Pain Med"},{"key":"R7-20251215","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.cmi.2025.04.045","article-title":"Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis.","volume":"31","author":"Prosty","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"R8-20251215","doi-asserted-by":"crossref","first-page":"106352","DOI":"10.1016\/j.jinf.2024.106352","article-title":"Efficacy and safety of antistaphylococcal penicillin or cephazolin-based combinations versus monotherapy for methicillin-susceptible Staphylococcus aureus infective endocarditis: a propensity score analysis of nationwide prospective cohort.","volume":"89","author":"Calder\u00f3n-Parra","year":"2024","journal-title":"J Infect"},{"key":"R9-20251215","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS.","volume":"118","author":"Potter","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"R10-20251215","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jaad.2025.02.031","article-title":"Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database.","volume":"92","author":"Joshi","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R11-20251215","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s15010-024-02248-3","article-title":"Safety evaluation of ceftazidime\/avibactam based on FAERS database.","volume":"52","author":"Zhang","year":"2024","journal-title":"Infection"},{"key":"R12-20251215","first-page":"1","article-title":"A real-world pharmacovigilance case\/non-case study of FDA adverse event reporting system events for mannitol.","author":"Jin","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"R13-20251215","doi-asserted-by":"crossref","first-page":"e0328076","DOI":"10.1371\/journal.pone.0328076","article-title":"Unveiling aducanumab\u2019s safety profile: a comprehensive pharmacovigilance analysis.","volume":"20","author":"Ji","year":"2025","journal-title":"PLoS One"},{"key":"R14-20251215","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1097\/JS9.0000000000002194","article-title":"Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database.","volume":"111","author":"Liu","year":"2025","journal-title":"Int J Surg"},{"key":"R15-20251215","doi-asserted-by":"crossref","first-page":"119010","DOI":"10.1016\/j.jep.2024.119010","article-title":"Ginkgo biloba extract safety: insights from a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.","volume":"337","author":"Yao","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"R16-20251215","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA).","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"R17-20251215","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jad.2025.03.017","article-title":"The real-world safety profile of sertraline: pharmacovigilance analysis of the FAERS database.","volume":"379","author":"Shu","year":"2025","journal-title":"J Affect Disord"},{"key":"R18-20251215","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12916-025-03913-6","article-title":"Adverse events in the nervous system associated with blinatumomab: a real-world study.","volume":"23","author":"Gao","year":"2025","journal-title":"BMC Med"},{"key":"R19-20251215","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1111\/jdv.20197","article-title":"Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.","volume":"39","author":"Godfrey","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R20-20251215","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2106\/JBJS.23.01431","article-title":"Reverse shoulder arthroplasty is superior to plate fixation for displaced proximal humeral fractures in the elderly: five-year follow-up of the DelPhi randomized controlled trial.","volume":"106","author":"Fraser","year":"2024","journal-title":"J Bone Joint Surg Am"},{"key":"R21-20251215","doi-asserted-by":"crossref","first-page":"e2451353","DOI":"10.1001\/jamanetworkopen.2024.51353","article-title":"\u03b2-Lactam inoculum effect in methicillin-susceptible staphylococcus aureus infective endocarditis.","volume":"7","author":"Jean","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R22-20251215","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1016\/j.jaip.2024.07.022","article-title":"The immediate and delayed maximal nonirritating skin testing concentrations of \u03b2-lactam antibiotics.","volume":"12","author":"Gonzalez-Estrada","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9s2","key":"R23-20251215","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/j.arth.2024.04.058","article-title":"Perioperative cefazolin for total joint arthroplasty patients who have a penicillin allergy: is it safe?","volume":"39","author":"Bukowski","year":"2024","journal-title":"J Arthroplasty"},{"key":"R24-20251215","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.bja.2024.01.044","article-title":"Epidemiology of perioperative anaphylaxis in France in 2017-2018: the 11th GERAP survey.","volume":"132","author":"Tacquard","year":"2024","journal-title":"Br J Anaesth"},{"key":"R25-20251215","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/antibiotics11020194","article-title":"Antibiotic prophylaxis for hepato-biliopancreatic surgery-a systematic review.","volume":"11","author":"Steccanella","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"R26-20251215","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijid.2023.10.019","article-title":"Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort.","volume":"137","author":"Herrera-Hidalgo","year":"2023","journal-title":"Int J Infect Dis"},{"key":"R27-20251215","doi-asserted-by":"crossref","first-page":"e0003923","DOI":"10.1128\/jcm.00039-23","article-title":"Retrospective evaluation of the association of oxacillin MIC on acute treatment outcomes with cefazolin and antistaphylococcal penicillins in methicillin-susceptible staphylococcus aureus bacteremia.","volume":"61","author":"Hess","year":"2023","journal-title":"J Clin Microbiol"},{"key":"R28-20251215","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jss.2020.11.005","article-title":"Pulsed ultrasound of the spleen prolongs survival of rats with severe intra-abdominal sepsis.","volume":"259","author":"Zhang","year":"2021","journal-title":"J Surg Res"},{"key":"R29-20251215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5114\/ada.2024.145284","article-title":"Evaluation of bacterial skin infections and difference analysis in T lymphocytes and inflammatory factors.","volume":"42","author":"Qin","year":"2025","journal-title":"Postepy Dermatol Alergol"},{"key":"R30-20251215","doi-asserted-by":"crossref","first-page":"101362","DOI":"10.1016\/j.ajogmf.2024.101362","article-title":"Evidence-based cesarean delivery: preoperative management (part 7).","volume":"6","author":"Mackeen","year":"2024","journal-title":"Am J Obstet Gynecol MFM"},{"key":"R31-20251215","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/cid\/ciad559","article-title":"Cefazolin for the treatment of central nervous system infections.","volume":"78","author":"Tunkel","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R32-20251215","doi-asserted-by":"crossref","first-page":"e0185724","DOI":"10.1128\/aac.01857-24","article-title":"Optimizing cefazolin dosing for central nervous system infections: insights from population pharmacokinetics and Monte Carlo simulations.","volume":"69","author":"Pitcock","year":"2025","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:02:12Z","timestamp":1765814532000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":32,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046293","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2025-08-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}